TORONTO and PHILADELPHIA - Medicus Pharma Ltd. (NASDAQ: MDCX), a biotech company with a current market capitalization of ...
Medicus Pharma Ltd ( (MDCX)) has shared an update. Medicus Pharma Ltd. has signed a non-binding letter of intent with Reliant AI Inc., a decision-intelligence firm founded by former DeepMind and ...
In April, Medicus Pharma Ltd. (NASDAQ:MDCX) agreed to acquire all of Antev’s issued and outstanding shares on a share exchange. Antev is a clinical-stage biotech company developing Teverelix, a ...
PHILADELPHIA, PA / ACCESS Newswire / December 5, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the ...
The latest price target for Medicus Pharma (NASDAQ:MDCX) was reported by D. Boral Capital on December 15, 2025. The analyst firm set a price target for $27.00 expecting MDCX to rise to within 12 ...
Over the last year, a good number of insiders have significantly increased their holdings in Pro Medicus Limited (ASX:PME). This is encouraging because it indicates that insiders are more optimistic ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results